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Abstract: The endothelium is characterized by a wide range of important homeostatic functions. 
It participates in the control of hemostasis, blood coagulation and ﬁ  brinolysis, platelet and leuko-
cyte interactions with the vessel wall, regulation of vascular tone, and of blood pressure. Many 
crucial vasoactive endogenous compounds are produced by the endothelial cells to control the 
functions of vascular smooth muscle cells and of circulating blood cells. These complex systems 
determine a ﬁ  ne equilibrium which regulates the vascular tone. Impairments in endothelium-
dependent vasodilation lead to the so called endothelial dysfunction. Endothelial dysfunction is 
then characterized by unbalanced concentrations of vasodilating and vasoconstricting factors, 
the most important being represented by nitric oxide (NO) and angiotensin II (AT II). High 
angiotensin-converting enzyme (ACE) activity leads to increased AT II generation, reduced NO 
levels with subsequent vasoconstriction. The net acute effect results in contraction of vascular 
smooth muscle cells and reduced lumen diameter. Furthermore, when increased ACE activity 
is chronically sustained, increase in growth, proliferation and differentiation of the vascular 
smooth muscle cells takes place; at the same time, a decrease in the anti-proliferative action by 
NO, a decrease in ﬁ  binolysis and an increase in platelets aggregation may be observed. AT II 
is then involved not only in the regulation of blood pressure, but also in vascular inﬂ  ammation, 
permeability, smooth muscle cells remodelling, and oxidative stress which in turn lead to 
atherosclerosis and increased cardiovascular risk. Given the pivotal role exerted by AT II in 
contributing to alteration of endothelial function, treatment with ACE inhibitors or angiotensin 
receptor blockers (ARBs) may be of particular interest to restore a physiological activity of endo-
thelial cells. In this view, the blockade of the renin-angiotensin system (RAS), has been shown 
to positively affect the endothelial function, beyond the antihypertensive action displayed by 
these compounds. In this review, attention has been speciﬁ  cally focused on an ARB, irbesartan, 
to examine its effects on endothelial function.
Keywords: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, endothelial 
dysfunction, irbesartan
Introduction
The endothelium is a monolayer that covers the inner surface of the entire vascular 
system; its total weight is more than a liver, and if extended, it covers various tennis 
courts area. Other than being a barrier between blood and tissues, endothelial cells 
have multiple functional activities, that are impaired in common diseases like hyper-
tension, diabetes, and the metabolic syndrome. The main feature of the endothelial 
dysfunction is an impaired endothelium-dependent vasodilation, that is mainly due 
to reduced nitric oxide (NO) availability and increased angiotensin II (AT II) levels. 
This altered balance induces an increase of oxidative stress, free radicals, inﬂ  amma-
tion, and coagulation. In this picture, the use of angiotensin-receptor blockers (ARBs) 
or angiotensin-converting enzyme inhibitors (ACEis), has demonstrated that these 
drugs display multiple beneﬁ  cial effects on endothelial function; then, while in the 
past, the blood pressure control was considered the most important therapeutic target, Vascular Health and Risk Management 2008:4(1) 90
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nowadays these drugs have shown such favorable effects on 
the endothelial cells that these properties can not be consid-
ered just ancillary.
Endothelial function
Endothelial cells line the internal lumen of all the vasculature 
and serve as an interface between circulating blood and 
vascular smooth muscle cells. Other than being a physical 
barrier between blood and tissues, the endothelium displays 
multiple interactions with vascular smooth muscle cells 
and blood components. Then the endothelium cannot be 
considered just as a barrier, as it plays a pivotal role in 
vasculature function: it is involved in vasodilation and 
vasoconstriction, inﬂ  ammation, regulation of the thrombotic 
state, proliferation, and apoptosis of vascular smooth muscle 
cells (Haller 1997; De Meyer and Herman 1997).
Among the functions of endothelial cells, the NO 
production is certainly one of the most important. NO 
is a free radical produced from an essential amino acid, 
L-arginine, which in turn is converted in L-citrulline and 
subsequent production of NO (Palmer et al 1987) (Figure 1). 
This reaction is catalyzed by the endothelial NO synthase 
(eNOS). The physiologic event that leads to an increased 
activity of eNOS is represented by the shear stress, ie, the 
force produced by the blood ﬂ  ow per surface unit of the 
vascular wall (Vallance et al 1989). Once produced, NO 
diffusing in vascular smooth muscle cells, activates the 
guanylate cyclase (cGMP), which induces relaxation and 
then vasodilation. Other relevant effects of NO include inhi-
bition of platelets activation, limitation of vascular smooth 
muscle cells proliferation, monocytes adhesion, platelets 
aggregation, and apoptosis of endothelial cells (Radomski 
et al 1987a; Garg and Hassid 1989). Other factors with 
vasodilating action are represented by prostacyclins and 
hyperpolarizing factor (EDHF). The prostacyclin PGI2 is 
the main prostaglandin produced by the endothelium; its 
functions are represented by vasodilation, inhibition of 
platelets aggregation, and inhibition of vascular smooth 
Figure 1 Regulatory mechanisms of endothelial NO production.  Reproduced with permission from Yang Z, Ming XF. 2006. Recent advances in understanding endothelial 
dysfunction in atherosclerosis. Clin Med Res, 4:53–65. Copyright © 2006 Marshﬁ  eld Clinic.Vascular Health and Risk Management 2008:4(1) 91
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muscle cells proliferation (Moncada and Higgs 1987). EDHF 
is an endothelium-derived factor which exerts a vasodilating 
action mainly on small vessels, and whose action is reduced 
in presence of diabetes (Chen et al 1988; Matsumoto et al 
2003). As endothelial cells contribute to regulate the vascular 
tone, they are able to produce not only vasodilating but also 
vasoconstricting factors. AT II exerts opposite actions in 
respect to NO in the regulation of the vascular tone (Dzau 
1989). AT II induces at vascular level proliferation and 
migration of smooth muscle cells; furthermore, it is involved 
in the production of reactive species of oxygen (ROS), such 
altering the NO mediated vasodilation (Luscher and Tanner 
1993). AT II, other than determining the proliferation and 
migration of vascular smooth muscle cells, induces the 
expression of adhesion molecules and chemokines which 
mediate the adhesion and the migration of the monocytes 
in the vascular wall (Tummala et al 1999; Kintscher et al 
2001). The key enzyme that regulates the local generation 
of AT II is the angiotensin-converting enzyme (ACE). This 
proteolytic enzyme is synthesized by the endothelial cells 
and exerts its activity upon the blood-borne angiotensin I. 
AT II binds to and regulates vascular smooth muscle cells 
tone via speciﬁ  c angiotensin receptors (Studdy et al 1983). 
Elevated ACE concentrations antagonize NO activity not 
only by increasing AT II generation but also by decreasing 
concentrations of bradykinin (Mombouli 1997). High ACE 
activity leads to vasoconstriction due to reduced NO levels 
and increased AT II generation. The net acute effect results 
in contraction of vascular smooth muscle cells and reduced 
lumen diameter. Furthermore, when increased ACE activity 
is chronically sustained, a stimulation of growth, prolif-
eration, and differentiation of the vascular smooth muscle 
cells takes place; at the same time, a decrease in the antip-
roliferative action by NO, a decrease in ﬁ  binolysis and an 
increase in platelets aggregation may be observed. Another 
factor involved in vascular tone regulation is represented by 
endothelin-1 (ET-1) (Yanagisawa et al 1988). ET-1 induces 
vasodilation at low concentrations while vasoconstriction 
at high concentrations (Seo et al 1994). The interactions of 
ET-1 with its receptors, ETA and ETB, are responsible either 
for vasoconstriction, or induction of vascular smooth muscle 
cells proliferation (Arai et al 1990; Sakurai et al 1990). Other 
factors which display vasoconstricting properties are trom-
boxane A2 and prostaglandin H2, which represent products 
of the cyclooxygenase pathway. Both these factors exert 
actions which antagonize NO and prostacyclin activities not 
just at endothelial level but also at vascular smooth muscle 
cells and platelets level. Furthermore, the cyclooxygenase 
pathway represents a source of anion superoxide which in 
turn is a potent NO inactivator (Juliet et al 2003). Under 
physiologic conditions PGI2 and NO prevent platelets aggre-
gation and adhesion to the endothelium, such underlining 
a key role exerted by the endothelial cells in the regulation 
of the coagulative state. Of note, NO inhibits monocytes 
adhesion to vascular wall, an event that triggers the devel-
opment of atherosclerotic plaque (Böger et al 2000). Then, 
one of the actions exerted by endothelial cells concerns 
coagulation. Physiologically, the most important activator 
of the conversion of plasminogen to plasmin is the tissue 
plasminogen activator (t-PA). This peptide has a critical role 
in the dissolution of clots and maintenance of vessel lumen. 
The most important regulator of t-PA is the plasminogen 
activator inhibitor-1 (PAI-1) (Dawson and Henney 1992). 
AT II is able to stimulate platelets aggregation and to induce 
a procoagulative state by the activation of PAI-1 expression 
(Vaughan et al 1995).
The endothelium is also involved in the production of 
speciﬁ  c molecules which may have a role in inﬂ  ammation 
(Biegelsen and Loscalzo 1999). The most important are the 
intracellular adhesion molecule (ICAM) and vascular cell 
adhesion molecule (VCAM). These molecules act attract-
ing and anchoring those cells involved in the inﬂ  ammatory 
reaction. Not by chance, the atherosclerotic process is asso-
ciated with increased levels of acute phase proteins (Tracy 
et al 1997).
Endothelial dysfunction
Endothelial dysfunction is characterized by a defect in 
endothelium-dependent vasodilation which precedes a series 
of structural changes of the vascular wall. It may occur at any 
level in the arterial system and contribute to the development 
and progression of atherosclerosis by favoring coagulation, 
cells adhesion, and inﬂ  ammation, by promoting inappropri-
ate vasoconstriction, and/or vasodilation, and by enhancing 
trans-endothelial transport of atherogenic lipoproteins. The 
main alteration ascribable to the endothelial dysfunction is 
a reduced (or absent) availability of NO, essentially as a 
consequence of increased oxidative stress. The endothelial 
dysfunction may contribute to the onset and progression 
of atherosclerosis and several studies have reported that 
endothelial dysfunction represents an independent predic-
tor of cardiovascular events not only at coronary district but 
also in peripheral vasculature (Perticone et al 2001; Gokce 
et al 2002).
Hypertension is a pathological condition which activates 
endothelial cells leading to the production of contracting Vascular Health and Risk Management 2008:4(1) 92
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factors, including thromboxane A2, prostaglandin H2, 
cyclooxigenase-derived endothelium-dependent contracting 
factors (ECDF), and oxygen free radicals, which antagonize 
the relaxing activity of NO (Miller and Vanhoutte 1985; 
Aldere et al 1986; Katusic and Vanhoutte 1989). Furthermore, 
oxygen free radicals can impair endothelial function by 
causing NO breakdown (Gryglewski et al 1986).
Endothelial dysfunction has been extensively explored 
by evaluating the response to pharmacological or mechani-
cal endothelium-dependent stimuli (Lüscher and Noll 1996). 
Impaired response to acetylcholine, methacholine, bradyki-
nin, and substance P has been documented in the forearm 
vasculature of essential hypertensive patients compared with 
normotensive controls (Linder et al 1990; Panza et al 1990; 
Panza et al 1993a, b, c; Taddei et al 1994; Creager and Roddy 
1994; Panza et al 1995; Taddei et al 1995; Taddei et al 1997). 
Since in the same experimental conditions the vasodilating 
effect of an endothelium-independent vasodilator such as 
sodium nitroprussiate was found to be preserved, this line of 
evidence clearly indicates the presence of endothelial dys-
function in essential hypertension. Moreover, the evidence 
that reduced response to acetylcholine is detected in young 
normotensive offspring of essential hypertensive patients, 
and that this abnormality does not correlate with blood pres-
sure levels, suggests that impaired endothelium-dependent 
vasodilation, may be at least in part, genetically determined 
(Taddei et al 1996). Both the animal and human data strongly 
suggest that the production of COX-dependent EDCF is one 
of the principal mechanisms leading to an impaired avail-
ability of NO, at least in aging or essential (spontaneous) 
hypertension. Therefore, endothelial dysfunction accompa-
nied by the production of EDCF must play a key role in the 
progression of cardiovascular disease (Radomski et al 1987a, 
b; Dubey and Lucher 1993; Kubes et al 1991; De Caterina 
et al 1995). NO is an important autoregulatory inhibitor of 
inﬂ  ammation (Napoli and Ignarro 2001). It limits oxidative 
stress in the microvasculature through its ability to scavenge 
ROS (Miles et al 1996). Noteworthy, even if the relationship 
between angiotensin receptors and NO is not fully clear, it has 
to be outlined that ACEis and ARBs exerted protective effects 
on AT II-mediated inﬂ  ammatory response (Tamarat et al 
2002; Chen et al 2003). Interestingly, there is accumulating 
evidence to suggest a central role for inﬂ  ammatory response 
in the pathogenesis of endothelial dysfunction, hypertension, 
and coronary artery disease. Elevated C-reactive protein 
(CRP) and interleukin-6 (IL-6) levels have been shown to be 
related with a poor outcome in patients with unstable angina, 
probably reﬂ  ecting an important inﬂ  ammatory component in 
the pathogenesis of this condition (Liuzzo et al 1994; Liuzzo 
et al 2001). A large number of studies has demonstrated that 
AT II is involved in key events of the inﬂ  ammatory process. 
AT II increases vascular permeability (by the release of 
prostaglandins and vascular endothelial cell growth factor 
or rearrangement of cytoskeletal proteins) that initiates the 
inﬂ  ammatory process (Baylis and Brenner 1978; Ichikawa 
and Harris 1991; Schramek et al 1995). AT II contributes to 
the recruitment of inﬂ  ammatory cells into the tissue through 
the regulation of adhesion molecules and chemokines by 
resident cells (Pastore et al 1999; Piqueras et al 2000; Pueyo 
et al 2000). Moreover, AT II could directly activate inﬁ  ltrat-
ing immunocompetent cells, including chemotaxis, differ-
entiation and proliferation (Diet et al 1996; Hansson 2001; 
Costantinescu et al 1998). Additional data suggest that RAS 
activation could play a certain role even in immunologically-
induced inﬂ  ammation (Rodriguez-Iturbe et al 2001). Finally, 
AT II participates in tissue repair and remodeling, through 
the regulation of cell growth and matrix synthesis (Egido 
1996; Nakamura et al 2000; Tunon et al 2000; Border 
and Noble 2001; Wolf et al 2002). In summary, there are 
evidences enough to support the hypothesis that RAS is key 
mediator of inﬂ  ammation. AT II is then involved not only in 
the regulation of blood pressure, but also in vascular inﬂ  am-
mation, permeability, smooth muscle cells remodelling, and 
oxidative stress which lead to atherosclerosis and increase 
cardiovascular risk. While in the past, AT II was considered 
as a circulating factor, playing a central role in the regulation 
of blood pressure and electrolyte homeostasis, it has been 
later ascertained that non-ACE pathways exist and function 
to generate about 40% of the total AT II (Campbell 1987; 
Johnston 1992; Gibbons and Dzau 1994; Hollenberg et al 
1998; Padmanabhan et al 1999). In fact, vascular inﬂ  amma-
tory response has been shown to be more closely related to 
local AT II than circulating AT II, and recent studies tried 
to elucidate the consequences of increased AT II production 
within speciﬁ  c organs (heart, vasculature, pancreas, adipose 
tissue) (Bader et al 2001; Fleming et al 2006). These data 
indicate that there is a remarkable production of AT II by 
tissues and that a complete suppression of the RAS cannot 
be achieved by ACE inhibition alone (Petrie et al 2001). 
Inhibition of the RAS by blockade at the AT-1 receptor 
should, theoretically, result in more complete inhibition of the 
adverse cardiovascular effects of AT II. On the other hand, 
ACEis also inhibit the enzyme kininase II, which is respon-
sible for the degradation of bradykinin (Erdos 1975) (Figure 
2). Several studies have emphasized the possible role of ele-
vated bradykinin levels resulting from ACE inhibitor therapy. Vascular Health and Risk Management 2008:4(1) 93
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Favorable hemodynamic effects mediated by bradykinin may 
include venodilation, vasodilation (coronary and systemic), 
improved left ventricular relaxation, and contractile func-
tion (Trippodo et al 1995; Hornig et al 1998; Cheng 1998). 
Other potential beneﬁ  ts of bradykinin include a reduction in 
ventricular dilatation and cardiac hypertrophy, an increase 
in levels of endogenous tissue plasminogen activator, and 
an improvement in abnormal endothelial function (Mancini 
et al 1996; Schlaifer et al 1997). An additional evidence of 
the importance of the bradykinin system in ACE inhibition 
comes from a study by Guazzi et al (1997). The authors 
showed that although losartan and enalapril had similar 
hemodynamic and clinical effects, the action of enalapril 
was antagonized by aspirin, whereas that of losartan was not. 
This may be related to the role of the bradykinin in mediating 
prostaglandin release. But bradykinin has been blamed for 
some of the undesirable complications of ACEis such as 
cough and angioedema. Cough may occur in up to 10% of 
patients treated with ACEis, while angioedema represents a 
potentially lethal complication (Israili and Hall 1992; Fox 
et al 1996). By directly blocking AT-1 receptors, ARBs can 
inhibit the action of AT II while having little or no effect on 
the bradykinin system (Brooks and Ruffolo 1999).
Hypertension is a common condition which is often 
associated with obesity, diabetes, and dyslipidemia. There is 
much evidence in support of an activation of the RAS in 
obesity. This has led to the notion that blockade of the RAS 
might be a beneﬁ  cial strategy for management of hyperten-
sion associated with obesity (Sharma 2004). Adipose RAS 
has recently received much attention because experimental 
Figure 2 Relationships between angiotensin and kinin cascades.
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evidence has shown its involvement in the pathophysiology 
of obesity-induced hypertension. In mice, adipocyte-derived 
angiotensinogen can act locally to affect adipocyte growth 
and differentiation and can also be secreted into the blood-
stream, contributing to the circulating pool of angiotensino-
gen (Massiera et al 2001). The demonstration that 
angiotensinogen produced by the adipose tissue may be 
released in the bloodstream suggests that the high circulating 
levels of angiotensinogen associated with obesity may be 
attributable in part to increased fat mass. Mice with obesity 
induced by a high-fat diet exhibit greater angiotensinogen 
gene expression in intra-abdominal fat but not in other fat 
depots or non-adipose tissues (Rahmouni et al 2004). Interest-
ingly, increased production of angiotensinogen by intra-
abdominal fat appears to explain the high circulating levels 
of this peptide observed in dietary obesity (Boustany et al 
2004). Activation of adipose RAS is also involved in 
development of high blood pressure in transgenic mice used 
as a model of visceral obesity. These transgenic mice show 
an increase in enzyme activity similar to that seen in obese 
humans and replicate visceral fat accumulation and high 
blood pressure (Masuzaki et al 2003). The hypertension 
observed in this model was abolished by selective AT receptor 
blockade. The above-mentioned data establish that adipose 
RAS plays an important role in the association between 
obesity and hypertension. This activation of adipose RAS 
may also explain the link between excessive visceral fat and 
cardiovascular diseases. Endothelial dysfunction is a typical 
feature of the states of insulin resistance and not by chance, 
and obesity is associated with elevated plasma levels of 
ET-1 (Steinberg et al 1996; Ferri et al 1996). Caballero et al 
(1999) demonstrated early abnormalities in vascular reactiv-
ity and biochemical markers of endothelial cells activation 
in individuals at risk of developing diabetes. The investigators 
measured the increase in blood ﬂ  ow in the microcirculation 
(laser Doppler ﬂ  owmetry) and in the macrocirculation (ultra-
sound) in four groups of subjects: 1) healthy normoglycemic 
individuals with no history of type 2 diabetes in a ﬁ  rst-degree 
relative (controls); 2) healthy normoglycemic subjects with 
a history of type 2 diabetes in one or both parents; 3) subjects 
with impaired fasting glucose; and 4) patients with type 2 
diabetes without vascular complications. Moreover the 
investigators measured plasma concentrations of ET-1, sol-
uble intercellular adhesion molecule (sICAM), and soluble 
vascular cell adhesion molecule (sVCAM), as indicators of 
endothelial cells activation. The vasodilatatory responses to 
acetylcholine were reduced in groups 2, 3, and 4 compared 
with controls and ET-1 was signiﬁ  cantly higher in these three 
groups. These results suggest that abnormalities in vascular 
reactivity and biochemical markers of endothelial cells 
activation are present early in individuals at risk of develop-
ing type 2 diabetes, even at stage when normal glucose toler-
ance exists. Hyperglycemia can cause endothelial dysfunction 
not only in already diagnosed diabetes but also in mild and 
transient increases of blood glucose, as demonstrated in stud-
ies carried on healthy volunteers undergoing hyperglycemic 
clamp (Williams et al 1998). The crucial point that determines 
endothelial dysfunction, without structural alterations of the 
vascular wall, is the reduced availability of NO. Insulin exerts 
its vascular effects primarily by increasing the availability 
of NO. In experimental conditions of insulin resistance, 
endothelial-mediated vasodilation is impaired, because of 
insulin’s inability to stimulate the activity of eNOS (Vincent 
et al 2003; Shaul 2002). In the presence of diabetes, several 
factors may alter NO availability: increased production of 
oxygen free radicals, increased levels of asymmetric dimeth-
ylarginine (ADMA), which is an irreversible inhibitor of 
NOS, activation of protein-kinase C (PKC), and accelerated 
production of advanced products of glycosilation (AGEs) 
(Brownlee 1992; Surdacki et al 2007). Since 1992, ADMA 
has been recognized as an endogenous inhibitor of eNOS, 
and in vitro experiments demonstrated that the NO production 
is inhibited by ADMA in a concentration-dependent manner 
(Vallance et al 1992). In fact, ADMA represents a cardio-
vascular risk factor: it is a strong predictor of cardiovascular 
events and total mortality in hemodialysis patients; high 
ADMA concentrations are related to increased risk of death 
in patients on intensive care unit, and it predicts the outcome 
after percuteneous coronary intervention in patients with 
stable angina pectoris (Zoccali et al 2001; Nijveldt et al 2003; 
Lu et al 2003). It has become more and more evident that the 
production of free oxygen radicals plays a pivotal role in the 
development of vascular complications of diabetic disease 
(Ceriello 2006). In vitro studies suggest that endothelial cells 
exposed to high glucose levels increase the production of 
superoxide and show alterations of the cell proliferation, 
which may be completely prevented by the increase in the 
expression of endogenous anti-oxidants (Nishikawa et al 
2000; Zanetti et al 2001). Diabetic patients are particularly 
exposed to the endothelial damage from free radicals also 
because they show a reduction of anti-oxidant defences, 
including a reduction of superoxide dismutase (Crouch et al 
1978). Another important mediator of endothelial dysfunction 
in diabetes is represented by the activation of PKC. In pres-
ence of hyperglycemia high levels of diacylglycerol activate 
PKC which in turn induces alterations of eNOS activity and Vascular Health and Risk Management 2008:4(1) 95
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NADPH oxidase, and then contributes to an elevated produc-
tion of free oxygen radicals and to an increase in oxidative 
stress (Hink et al 2001). NADPH is required for proper NO 
generation; hyperglycemia may lead to intracellular changes 
in the redox state with activation of PKC resulting in deple-
tion of the cellular NADPH pool (Williamson et al 1993). If 
acute hyperglycemia induces endothelial dysfunction mostly 
by worsening oxidative stress, chronic hyperglycemia exerts 
further deleterious effects on vascular wall by production of 
AGEs. It has been demonstrated that in the presence of dia-
betes, AGEs accumulation is able to inhibit NO production 
producing defective endothelium-dependent vasodilation 
(Bucala et al 1991). Furthermore, the binding of AGEs with 
their cell receptors, receptors for advanced glycation end-
products (RAGE) and AGE-R3, may induce endothelial 
activation with consequent production of growth factors and 
pro-inﬂ  ammatory molecules, which lead to development and 
progression of atherosclerotic process (Kislinger et al 2001). 
The inﬂ  ammatory component in diabetic patients is particu-
larly harmful, given the progression towards atherosclerosis. 
Proinﬂ  ammatory cytokines, like tumor necrosis factor-α 
(TNF-α), inhibit insulin-stimulated activation and expression 
of eNOS resulting in diminished levels of NO (Kim et al 
2001; Anderson et al 2004). In vitro studies have demon-
strated that CRP, which is particularly elevated in diabetic 
patients, induces direct damage at the endothelial level lead-
ing to a reduction in NO and vasodilating prostaglandins and 
an increase in ET-1. Furthermore, proinﬂ  ammatory cytokines 
like TNF-α and IL-6 have demonstrated a detrimental effect 
at the endothelial level (Picchi et al 2006). In humans, the 
relationships between inﬂ  ammation, endothelial dysfunction, 
and hyperglycemia were outlined in the Hoorn Study, a 
population-based cohort study. Results showed that type 2 
diabetes was associated with both endothelial dysfunction 
and low-grade inﬂ  ammation, whereas impaired glucose 
tolerance was associated only with low-grade inﬂ  ammation. 
These ﬁ  ndings were independent of other risk factors that 
accompany diabetes. Furthermore, endothelial dysfunction 
and low-grade inﬂ  ammation were associated with a greater 
risk of cardiovascular mortality, especially in diabetic 
patients; and, ﬁ  nally, diabetes-associated endothelial dysfunc-
tion and low-grade inﬂ  ammation explained about 43% of the 
greater cardiovascular mortality risk conferred by type 2 
diabetes (de Jager et al 2006). Not by chance, diabetic patients 
with myocardial infarction, compared with non-diabetic 
patients, show impaired endothelium-dependent vasodilation, 
lower adiponectin levels, and higher concentrations of TNF-
α and IL-6 (Nystrom et al 2006). Therefore, not only obesity, 
but also diabetes, are associated with proinﬂ  ammatory states 
characterized by increased circulating markers of inﬂ  amma-
tion as well as inﬁ  ltration of adipose tissue with activated 
macrophages (Weisberg et al 2003; Xu et al 2003). In par-
ticular, CRP has been identiﬁ  ed as a risk factor for develop-
ing type 2 diabetes, and its levels are correlated with 
cardiovascular risk (Pradhan et al 2001; Saito et al 2003) 
(Figure 3).
Effects of irbesartan on endothelial 
dysfunction
In vitro and in vivo studies have explored the effects of 
ARBs on endothelial dysfunction. One of the most studied 
ARB is irbesartan, whose action has been proven to be 
beneﬁ  cial in ameliorating endothelial function above all in 
hypertension and diabetes, two frequent diseases in which 
alterations of endothelium homeostasis are typically present. 
In essential hypertensive patients, treatment with irbesartan 
promoted a signiﬁ  cant increase in endothelium-dependent 
and endothelium-independent vasodilation. In a study per-
formed by Bragulat et al (2003), hypertensive patients were 
examined at baseline and at the end of a 6-month period of 
irbesartan treatment. Endothelium-dependent and endothe-
lium-independent responses were determined by measuring 
changes in forearm blood ﬂ  ow (FBF) in response to intrar-
terial infusions of acetylcholine (endothelium-dependent 
vasodilation [EDV]), sodium nitroprusside (endothelium-
independent vasodilation [EIV]), with and without the 
addition of the NO synthase inhibitor L-NMMA. Irbesartan 
promoted a signiﬁ  cant increase in EDV and EIV. L-NMMA-
induced vasoconstriction was signiﬁ  cantly enhanced after 
irbesartan treatment. Plasma concentrations of endothelin 
fell signiﬁ  cantly after irbesartan treatment. In addition to 
a signiﬁ  cant increase in endothelium-dependent and endo-
thelium-independent vasodilation, irbesartan restored the 
vasoconstriction capacity of NO synthase inhibitors, sug-
gesting a direct effect on tonic NO release, and decreased 
endothelin production. These actions may play an important 
role in the vascular protecting effects of irbesartan. One of the 
crucial points in the use of antihypertensive drugs concerns 
their beneﬁ  cial effects beyond the reduction of blood pres-
sure. Given the pivotal role that AT II exerts in determining 
endothelial dysfunction, it is reasonable that ACEis and 
ARBs may have some additive and favorable effects on endo-
thelium. For example, when irbesartan has been compared 
with the beta-blocker atenolol, results have shown that both 
were able to improve endothelium-dependent vasodilation, 
but only irbesartan was able to reduce ﬁ  brinogen, PAI-1, Vascular Health and Risk Management 2008:4(1) 96
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and thrombomodulin. These results showed that, despite an 
equally controlled blood pressure, the ARB treatment was 
associated with a more favorable modiﬁ  cation of hemostatic/
ﬁ  binolytic status (Makris et al 2000; von zur Muhlen et al 
2001). The hypothesis that the blockade of AT-1 receptor 
may exert a protective effect on vasculature was also tested 
in a study that compared equihypotensive doses of irbesar-
tan and amlodipine in apolipoprotein E-null mice, rendered 
diabetic by streptozotocin. Diabetes was associated with 
an increase in plaque area and complexity in the aorta, in 
association with a signiﬁ  cant increase in aortic AT-1 recep-
tor expression, cellular proliferation, collagen content, and 
macrophage-positive and alpha-smooth muscle actin-posi-
tive cell inﬁ  ltration, as well as an increased expression of 
platelet-derived growth factor-B (PDGF-B), monocyte che-
moattractant protein-1 (MCP-1), and vascular cell adhesion 
molecule-1 (VCAM-1). Irbesartan but not amlodipine treat-
ment attenuated the development of atherosclerosis, collagen 
content, cellular proliferation, and macrophage inﬁ  ltration as 
well as diabetes-induced AT-1 receptor, PDGF-B, MCP-1, 
and VCAM-1 overexpression in the aorta, despite similar 
blood pressure reductions by both treatments (Candido et al 
2004). It has been also demonstrated that irbesartan exerts a 
favorable effect on vascular inﬂ  ammation, which is a feature 
of endothelial dysfunction and promotes the development of 
atherosclerosis. In diabetic patients, irbesartan 300 mg/day 
alone or in combination with atorvastatin 40 mg/day was 
able to signiﬁ  cantly increase ﬂ  ow-mediated dilatation while 
decreasing nitrotyrosine, CRP, ICAM-1, and IL-6; these 
beneﬁ  cial effects on endothelial function were more marked 
when irbesartan was associated with atorvastatin (Ceriello 
et al 2005). The effects on vascular inﬂ  ammation in type 
2 diabetic patients were further assessed in the IRMA 2 
substudy, a 2-year, multicenter, randomized, double-blind 
trial which compared irbesartan (150 or 300 mg/day) versus 
placebo. A subgroup (n = 269) was analyzed for biomarkers 
of inﬂ  ammatory activity at baseline and after 1 and 2 years. 
In this substudy, irbesartan was able to reduce markers of 
inﬂ  ammatory activity, ie, CRP and ﬁ  brinogen; IL-6 showed 
a 1.8% increase per year compared with a 6.5% increase for 
placebo, and changes in IL-6 were associated with changes 
in albumin excretion. There was no treatment effect on the 
other biomarkers (ICAM, VCAM, E-selectin, trasforming 
growth factor-β, and AGEs). Then, in this study, irbesartan 
Figure 3 Factors contributing to endothelial dysfunction in type 2 diabetes.
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Arterial stiffness
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(300 mg/day) reduced low-grade inﬂ  ammation in diabetic 
patients, possibly reducing the risk of micro- and macrovas-
cular disease (Persson 2006). The ISLAND study (Irbesartan 
and Lipoic Acid in Endothelial Dysfunction) evaluated the 
ability of irbesartan and lipoic acid, an antioxidant, to affect 
endothelial function and inﬂ  ammation in patients with the 
metabolic syndrome. Treatment with irbesartan signiﬁ  cantly 
ameliorated the endothelium-dependent vasodilation by 67%, 
treatment with lipoic acid by 44%, and combined treatment 
by 75%. In this study the two drugs reduced markers of 
inﬂ  ammation such as IL-6 and PAI-1, while just irbesartan 
signiﬁ  cantly reduced plasma levels of isoprostane-8, a marker 
of oxidative stress. Of note, these results were independent 
of blood pressure values, underlining the direct effects of 
AT-1 receptor blockade (Sola et al 2005). The increased 
cardiovascular risk encountered by women during the 
menopause is associated with endothelial dysfunction. It 
has been demonstrated that in ovariectomized rats, estrogen 
replacement therapy prevents endothelial dysfunction, and 
that irbesartan exerts a similar protective action, reducing 
oxidative stress and increasing NO availability (Wassmann 
et al 2001; Riveiro et al 2002). Of particular interest are the 
studies concerning the effects of ARBs on myocardial vas-
culature. One study evaluated the effect of irbesartan on the 
coronary and peripheral endothelial function in patients with 
coronary artery disease (CAD). Blockade of AT-1 receptor 
signiﬁ  cantly improved ﬂ  ow-mediated dilation (FMD) of the 
brachial artery, while no changes in the coronary district were 
observed (Warnholtz et al 2006). It has to be noted that even 
if no signiﬁ  cant improvement in coronary endothelial func-
tion was detected, since reduced FMD of the brachial artery 
is associated with high cardiovascular event rate, improve-
ment of FMD may lead to better the prognosis in patients 
with CAD (Brevetti et al 2003). Two studies investigated 
endothelial function in congestive heart failure (CHF). In 
the ﬁ  rst, treatment either with trandolapril or irbesartan sig-
niﬁ  cantly improved endothelium-dependent relaxation in rat 
aortic rings, but just the ARB was able to reduce superoxide 
aortic formation (Schäfer et al 2004). In the second, left 
and right ventricular (LV and RV) coronary vasodilatation 
reserve (CVR) were investigated in rats with hypertension or 
CHF. Results showed that treatment with irbesartan had no 
early effects on LV and RV CVR, and improved RV CVR 
over the long term, mainly by limiting RV hypertrophy and 
by preventing the development of pericoronary ﬁ  brosis and 
coronary endothelial function (Richer et al 2001). Taken 
together these results lead to the conclusion that irbesartan 
treatment can ameliorate endothelial function not only in 
peripheral vasculature, but also in the coronary district, ie, 
that these properties have a cardiovascular protective effect 
beyond blood pressure reduction.
Perspectives and conclusions
Recent studies have addressed the fundamental role exerted 
by the endothelial progenitor cells (EPCs) in endothelial func-
tion and cardiovascular risk. EPCs are bone-marrow derived 
cells which are responsible for vascular repair (Kocher et al 
2001). It was observed a strong correlation between the 
number of circulating EPCs and the subjects’ combined 
Framingham risk factor score. Measurement of ﬂ  ow-medi-
ated brachial-artery reactivity also revealed a signiﬁ  cant 
relation between endothelial function and the number of 
progenitor cells, and the levels of circulating EPCs were a 
better predictor of vascular reactivity than was the presence or 
absence of conventional risk factors. In addition, endothelial 
progenitor cells from subjects at high risk of cardiovascular 
events had higher rates of in vitro senescence than cells from 
subjects at low risk (Hill et al 2003). Therefore, reduced EPCs 
concentrations are associated with endothelial dysfunction, 
and, most important, their levels represent a strong predic-
tor for the occurrence of cardiovascular events and death 
from cardiovascular causes (Werner et al 2005). In patients 
with high cardiovascular risk such as diabetic patients, the 
number and/or function of EPCs is signiﬁ  cantly altered, 
and importantly, EPCs’ proliferation is inversely related to 
HbA1c levels and duration of diabetes (Tepper et al 2002). 
Therefor, the chance of improving the number and/or func-
tion of EPCs represents a new frontier in the treatment of 
endothelial dysfunction. Just one study evaluated the effects 
of ARBs on EPCs. Bahlmann et al (2005) studied the effect 
of two ARBs, olmesartan and irbesartan, on the number of 
EPCs in diabetic patients. The main ﬁ  ndings of this study 
were that EPCs were reduced in diabetic patients compared 
with healthy controls, and just 4 weeks’ treatment with ARBs 
signiﬁ  cantly increased the number of EPCs. This evidence 
suggest that the stimulatory action on EPCs number may be 
of therapeutic relevance and may help explain the beneﬁ  cial 
effects of ARBs in preventing cardiovascular disease.
In conclusion, the pathophysiological basis of endothelial 
dysfunction outlines the crucial role exerted in particular by 
AT II and NO and the related increased risk of cardiovascular 
diseases. Studies globally agree on the protective effects 
induced by the blockade of RAS, and many of them involved 
irbesartan, demonstrating its beneﬁ  cial actions beyond the 
blood pressure control. In vitro and in vivo studies, in fact, 
have conﬁ  rmed that other than the classical and well known Vascular Health and Risk Management 2008:4(1) 98
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cardiovascular risk factors such as hypertension, cellular 
and molecular mechanism involving endothelial cells are 
pivotal for the development of atherosclerosis and coronary 
artery disease. The most recent discoveries help to explain 
and conﬁ  rm the cardiovascular protective effect derived 
from irbesartan treatment, and at the same time open new 
and fascinating perspectives of care.
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